Lower Cutoff Points for Montreal Cognitive Assessment Needed
17 Jan 2024
Clinical Result
WEDNESDAY, Jan. 17, 2024 -- The Montreal Cognitive Assessment (MoCA) cutpoints for identifying mild cognitive impairment (MCI) or dementia are inappropriately high in a diverse community setting, yielding a high false-positive rate, according to a study published online Jan. 10 in the Journal of the American Geriatrics Society.
Marnina B. Stimmel, Ph.D., from Albert Einstein College of Medicine in New York City, and colleagues examined the utility and discriminative validity of the Spanish and English MoCA versions to identify cognitive impairment among diverse community-dwelling older adults. The analysis included 231 older adults (aged 65 years and older; 43 percent Hispanic and 39 percent Black/African American) with cognitive concerns attending outpatient primary care.
The researchers found that neuropsychological assessment identified 90 participants as cognitively normal with subjective cognitive concerns (average MoCA, 19.9), 133 with MCI (average MoCA, 16.6), and eight with dementia (average MoCA, 10.6). The mean English MoCA average was 18.6 versus 16.7 for Spanish. There was a high false-positive rate using the published cutpoint ≤23 for MCI (79 percent). Using the English MoCA, ≤18.5 was identified as the score to identify MCI or dementia (65 percent sensitivity; 77 percent specificity) and ≤16.5 for the Spanish MoCA (64 percent sensitivity; 73 percent specificity).
"Lower Spanish and English MoCA cutpoints may improve diagnostic accuracy for identifying cognitive impairment in this group, highlighting the need for the creation and validation of accurate cognitive screeners for ethnoculturally and linguistically diverse older adults," the authors write.
One author disclosed ties to MedRhythms.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.